OBJECTIVE The pharmacokinetics of ciprofloxacin (CPFX) was studied in 22 patients with normal and impaired renal function after a single intravenous administration.METHODS The patients were randomly devided into four groups, basing on their creatinine clearance (CLCR) : group 1 (normal renal function), CLCR＞80 mL·min-1, n=6;group 2 (mild renal impairment), CLCR51～80 mL·min-1,n=5; group 3 (moderate renal impairment), CLCR20～50 mL·min-1,n=6;group 4 (severe renal impairment), CLCR＜20 mL·min-1,n=5.All patients in group 1, 2 and 3 received a single dose of 400 mg, and group 4 at 300 mg,respectively.CPFX were infused intravenously for 1 h.The serum concentrations of CPFX were determined by bioassay.RESULTS The apparent volumes of distribution were not significantly different from each other in the four groups (P＞0.05 ).AUC was 2.8 and 5.5 fold,t1/2αwas 2.8 and 2.9 fold, and t1/2β was 1.8 and 2.7 fold higher in groups 3 and 4 than those in group 1, significantly and respectively.CLS was 60% and 81% lower in group 3 and 4 than those in group 1.CONCLUSION A dose of 200 mg CPFX daily was suggested for patients with severely impaired renal function (CR＜20 mL·min-1).
Key words
ciprofloxacin /
impaired renal function /
pharmacokinetics /
bioassay
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1］王海燕主编. 肾脏病学. 第2版［M］.北京：人民卫生出版社，1996：598.
[2］凌骝，陆瑶华，曹杏娣，等.血清中环丙沙星的微量微生物测定法［J］.中国医院药学杂志，1997,17(1):32.
[3］Thomas C, Gasser MD,Steven C,et al.Pharmacokinetic study of ciprofloxacin in patients with impaired renal function［J］.Am J Med,1987,82(Suppl 4A):139.
[4］Shah A,Lettieri J, Blum R,et al.Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects［J］.J Antimicrob Chemother, 1996,38(1):103.
[5］Drusano GL,Weir M, Forrest A,et al.Pharmacokinetics of intravenously administered ciprofloxacin in patients with varying degrees of renal function［J］.Antimicrob Agents Chemother, 1987, 31:860.
[6］Rohwedder R,Bergan T,Thorsteinsson SB,et al.Transintestinal elimination of ciprofloxacin［J］.Chemotherapy,1990, 36(2):77.
[7］Roberts DE, Williams JD.Ciprofloxacin in renal failure［J］.J Antimicrob Chemother,1989, 23(6):82.
[8］Jones EM,Mcmulin CM, Hedges AJ,et al.The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis:the effect of renal function and intra-abdominal disease［J］.J Antimicrob Chemother,1997,40:121.
[9］李明亚，张银娣，沈国胜，等.正常人一次口服国产环丙沙星药代动力学研究［J］.中国临床药理学杂志，1992，8（4）：204.
[10］黄民，赵香兰. 环丙沙星的人体药代动力学研究［J］.中国抗生素杂志，1993，18（1）：59.
[11］Drusano GL, Plaisance KI, Forrest A,et al.Dose ranging study and constant infusion evaluation of ciprofloxacin［J］.Antimicrob Agents Chemother,1986,30(3):440.
[12］李淑芳，金虹，张相林，等.环丙沙星的抗生素后效应和抗生素后亚MIC效应［J］.中国医院药学杂志，1998，18（4）：148.
{{custom_fnGroup.title_en}}
Footnotes
{{custom_fn.content}}
